Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)

v3.7.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)
$ / shares in Units, shares in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
program
$ / shares
shares
Dec. 31, 2016
USD ($)
May 08, 2017
USD ($)
Aug. 31, 2014
USD ($)
Property, Plant and Equipment [Line Items]        
Working capital deficit $ 28,700,000      
Equity component of currently redeemable convertible notes 24,293,000 $ 29,563,000    
Consecutive trading days   50 days    
Discrete income tax benefit $ 900,000      
Note receivable, interest and principal reduction per dollar of value 0.50      
2019 convertible senior notes        
Property, Plant and Equipment [Line Items]        
Principal amount outstanding $ 245,000,000 $ 245,000,000    
2019 convertible senior notes | Senior Notes        
Property, Plant and Equipment [Line Items]        
Principal amount outstanding       $ 245,000,000.0
Interest rate (percent)       0.75%
Retained Earnings | Accounting Standards Update 2016-09        
Property, Plant and Equipment [Line Items]        
Cumulative effect of new accounting principle in period of adoption   17,900,000    
Retained Earnings | Accounting Standards Update 2016-09, Forfeiture Rate Component        
Property, Plant and Equipment [Line Items]        
Cumulative effect of new accounting principle in period of adoption   300,000    
Recurring        
Property, Plant and Equipment [Line Items]        
Assets, fair value 116,219,000 126,187,000    
Recurring | Investment in warrants        
Property, Plant and Equipment [Line Items]        
Assets, fair value 608,000 684,000    
Recurring | Note receivable Viking Therapeutics, Inc.        
Property, Plant and Equipment [Line Items]        
Assets, fair value 3,207,000 3,207,000    
Recurring | Fair Value, Inputs, Level 1        
Property, Plant and Equipment [Line Items]        
Assets, fair value 2,946,000 3,738,000    
Recurring | Fair Value, Inputs, Level 1 | Investment in warrants        
Property, Plant and Equipment [Line Items]        
Assets, fair value 608,000 684,000    
Recurring | Fair Value, Inputs, Level 1 | Note receivable Viking Therapeutics, Inc.        
Property, Plant and Equipment [Line Items]        
Assets, fair value 0 0    
Recurring | Fair Value, Inputs, Level 3        
Property, Plant and Equipment [Line Items]        
Assets, fair value 3,207,000 3,207,000    
Recurring | Fair Value, Inputs, Level 3 | Investment in warrants        
Property, Plant and Equipment [Line Items]        
Assets, fair value 0 0    
Recurring | Fair Value, Inputs, Level 3 | Note receivable Viking Therapeutics, Inc.        
Property, Plant and Equipment [Line Items]        
Assets, fair value $ 3,207,000 $ 3,207,000    
Viking Therapeutics, Inc.        
Property, Plant and Equipment [Line Items]        
Equity method investment, ownership (percent) 22.70%      
Market value of investment in Viking $ 6,800,000      
Outstanding warrants to purchase shares of Viking's common stock (shares) | shares 1.5      
Warrant exercise price (USD per share) | $ / shares $ 1.50      
Number of programs licensed to Viking | program 5      
Note receivable, stated interest rate (percent) 2.50%      
Note Receivable, Cash Repayment Due     $ 200,000